Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

1

PCSK9 inhibitors may enhance antitumor immunity and improve responses to immune checkpoint inhibitors in cancer treatment.
2

The study utilized a retrospective comparative effectiveness design to evaluate outcomes in patients receiving PCSK9 inhibitors versus high-intensity statins.
3

Primary outcomes included overall survival and major adverse cardiovascular events among patients treated with immune checkpoint inhibitors.
4

A total of 478 patients were analyzed after propensity score matching, balancing baseline characteristics between the two treatment cohorts.
5

The findings aim to clarify whether PCSK9 inhibitors can improve the efficacy of immune checkpoint inhibitors in cancer therapy.

Jama Network Open

1